Physician profile
Jeff Alexander
NPI 1518964097
$41,331.42
in general payments reported to CMS, 2019-2025
41 companies · $5,432 in 2025
The $5,432 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,087 · 2021: $11K · 2022: $11K · 2023: $5,222 · 2024: $6,282 · 2025: $5,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,153.20 |
| Food and Beverage | $2,782.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20,003.92 | 2019-2023 | |
| Abbvie INC. | $13,523.74 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $867.84 | 2019-2025 | Winlevi, Blu-U, Odomzo |
| Merz North America, INC. | $689.41 | 2019 | |
| Pfizer INC. | $640.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $627.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $485.99 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $439.42 | 2022-2025 | Sotyktu |
| Amgen INC. | $437.62 | 2020-2024 | Otezla |
| Mayne Pharma Commercial LLC | $415.42 | 2019-2024 | |
| Galderma Laboratories, L.P. | $341.55 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $305.40 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Almirall LLC | $300.06 | 2019-2023 | Seysara |
| Incyte Corporation | $298.37 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $261.71 | 2021-2025 | Tremfya |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.20 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Leo Pharma INC. | $172.08 | 2021-2023 | Adbry |
| Biofrontera INC. | $129.75 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $129.11 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $125.09 | 2023-2025 | Zoryve |
| Organogenesis INC. | $84.57 | 2023-2024 | Puraply Franchise, Puraply |
| Genzyme Corporation | $84.17 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $79.64 | 2019-2020 | |
| Abiomed | $74.97 | 2024 | Impella |
| Revance Therapeutics, INC. | $64.85 | 2025 | Daxxify |
| Botanix Sb INC | $55.88 | 2025 | Sofdra |
| Celgene Corporation | $51.94 | 2019 | |
| Dermira, INC. | $51.30 | 2020-2021 | |
| Organon LLC | $50.59 | 2025 | Vtama |
| Nabriva Therapeutics, Plc | $40.88 | 2020-2021 | |
| Medtronic, INC. | $40.28 | 2023 | Mcgrath Mac |
| Ucb, INC. | $32.01 | 2024-2025 | Bimzelx |
| Dusa Pharmaceuticals, INC. | $27.89 | 2019 | |
| Kyowa Kirin, INC. | $27.06 | 2023 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.30 | 2023 | Spevigo |
| Aclaris Therapeutics, INC. | $24.72 | 2019 | |
| Blueprint Medicines Corporation | $19.26 | 2023 | |
| Dermavant Sciences, INC. | $17.58 | 2023 | Vtama |
| Medline Industries Lp | $14.28 | 2023 | |
| Promius Pharma LLC | $12.98 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.